Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruochan, Pei, Siya, Chen, Yayu, Tan, Linxia, Xue, Ying, Liu, Shao, Huang, Yan, Fan, Xuegong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295557/
https://www.ncbi.nlm.nih.gov/pubmed/34307428
http://dx.doi.org/10.3389/fmed.2021.701061
_version_ 1783725453165461504
author Chen, Ruochan
Pei, Siya
Chen, Yayu
Tan, Linxia
Xue, Ying
Liu, Shao
Huang, Yan
Fan, Xuegong
author_facet Chen, Ruochan
Pei, Siya
Chen, Yayu
Tan, Linxia
Xue, Ying
Liu, Shao
Huang, Yan
Fan, Xuegong
author_sort Chen, Ruochan
collection PubMed
description Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.
format Online
Article
Text
id pubmed-8295557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82955572021-07-23 Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report Chen, Ruochan Pei, Siya Chen, Yayu Tan, Linxia Xue, Ying Liu, Shao Huang, Yan Fan, Xuegong Front Med (Lausanne) Medicine Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV. Frontiers Media S.A. 2021-07-08 /pmc/articles/PMC8295557/ /pubmed/34307428 http://dx.doi.org/10.3389/fmed.2021.701061 Text en Copyright © 2021 Chen, Pei, Chen, Tan, Xue, Liu, Huang and Fan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Chen, Ruochan
Pei, Siya
Chen, Yayu
Tan, Linxia
Xue, Ying
Liu, Shao
Huang, Yan
Fan, Xuegong
Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_full Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_fullStr Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_full_unstemmed Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_short Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_sort suboptimal response to tenofovir alafenamide in two patients with hbeag-positive hepatitis b: a case report
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295557/
https://www.ncbi.nlm.nih.gov/pubmed/34307428
http://dx.doi.org/10.3389/fmed.2021.701061
work_keys_str_mv AT chenruochan suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT peisiya suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT chenyayu suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT tanlinxia suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT xueying suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT liushao suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT huangyan suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT fanxuegong suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport

Ejemplares similares